Skip to main content

Advertisement

Log in

Metabolic syndrome components and colorectal adenoma in the CLUE II cohort

  • Original Paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Background

Metabolic syndrome components have been associated with colorectal cancer in several studies; however, evidence for colorectal adenomas is limited. Thus, we evaluated the association between markers of the metabolic syndrome with colorectal adenoma development in a nested case–control study.

Methods

Colorectal adenoma cases (n = 132) and matched controls, who had a negative sigmoidoscopy or a colonoscopy (n = 260), were identified between baseline in 1989 and 2000 among participants in the CLUE II cohort of Washington County, Maryland. Concentrations of C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, total cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured in baseline blood specimens. Body mass index was calculated using baseline height and weight. Use of medications to treat diabetes mellitus was self-reported at baseline. Blood pressure was measured at baseline. Distributional cutpoints of the latter markers were used to define the metabolic syndrome components (hyperinsulinemia, hyperglycemia, obesity, dyslipidemia, and hypertension) present at baseline.

Results

No statistically significant associations with adenomas were observed for the markers of the metabolic syndrome, with the exception of a strong positive association for use of diabetes medications (OR, 8.00; 95% CI, 1.70–37.67), albeit based on small numbers.

Conclusion

Our findings do not support that components of the metabolic syndrome influence risk of colorectal adenomas, except possibly for severe diabetes mellitus warranting medical treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Giovannucci E (2003) Diet, body weight, and colorectal cancer: a summary of the epidemiologic evidence. J Womens Health (Larchmt) 12:173–182

    Article  Google Scholar 

  2. Villegas R, Salim A, Flynn A, Perry IJ (2004) Prudent diet and the risk of insulin resistance. Nutr Metab Cardiovasc Dis 14:334–343

    Article  CAS  PubMed  Google Scholar 

  3. McKeown-Eyssen G (1994) Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomark Prev 3:687–695

    CAS  Google Scholar 

  4. Giovannucci E (1995) Insulin and colon cancer. Cancer Causes Control 6:164–179

    Article  CAS  PubMed  Google Scholar 

  5. Cowey S, Hardy RW (2006) The metabolic syndrome: a high-risk state for cancer? Am J Pathol 169:1505–1522

    Article  CAS  PubMed  Google Scholar 

  6. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H et al (2000) Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92:1592–1600

    Article  CAS  PubMed  Google Scholar 

  7. Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM et al (2004) A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 96:546–553

    CAS  PubMed  Google Scholar 

  8. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S (2007) Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case–control study: the Japan public health center-based prospective study. Int J Cancer 120:2007–2012

    Article  CAS  PubMed  Google Scholar 

  9. Jenab M, Riboli E, Cleveland RJ, Norat T, Rinaldi S, Nieters A et al (2007) Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition. Int J Cancer 121:368–376

    Article  CAS  PubMed  Google Scholar 

  10. Platz EA, Hankinson SE, Rifai N, Colditz GA, Speizer FE, Giovannucci E (1999) Glycosylated hemoglobin and risk of colorectal cancer and adenoma (United States). Cancer Causes Control 10:379–386

    Article  CAS  PubMed  Google Scholar 

  11. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ (2003) Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomark Prev 12:412–418

    CAS  Google Scholar 

  12. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N (2004) Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomark Prev 13:915–919

    Google Scholar 

  13. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE et al (2005) A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomark Prev 14:850–855

    Article  CAS  Google Scholar 

  14. Lin J, Ridker PM, Pradhan A, Lee IM, Manson JE, Cook NR et al (2005) Hemoglobin A1c concentrations and risk of colorectal cancer in women. Cancer Epidemiol Biomark Prev 14:3010–3012

    Article  CAS  Google Scholar 

  15. Stocks T, Lukanova A, Johansson M, Rinaldi S, Palmqvist R, Hallmans G et al (2007) Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond) 32:304–314

    Article  Google Scholar 

  16. World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, Washington, DC, pp 210–229

  17. Gaard M, Tretli S, Urdal P (1997) Blood lipid and lipoprotein levels and the risk of cancer of the colon and rectum. A prospective study of 62,173 Norwegian men and women. Scand J Gastroenterol 32:162–168

    Article  CAS  PubMed  Google Scholar 

  18. Jarvinen R, Knekt P, Hakulinen T, Rissanen H, Heliovaara M (2001) Dietary fat, cholesterol and colorectal cancer in a prospective study. Br J Cancer 85:357–361

    Article  CAS  PubMed  Google Scholar 

  19. Nomura AM, Stemmermann GN, Chyou PH (1991) Prospective study of serum cholesterol levels and large-bowel cancer. J Natl Cancer Inst 83:1403–1407

    Article  CAS  PubMed  Google Scholar 

  20. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR (2006) The metabolic syndrome and risk of incident colorectal cancer. Cancer 107:28–36

    Article  PubMed  Google Scholar 

  21. Bowers K, Albanes D, Limburg P, Pietinen P, Taylor PR, Virtamo J et al (2006) A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol 164:652–664

    Article  PubMed  Google Scholar 

  22. Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K (2002) Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomark Prev 11:385–391

    Google Scholar 

  23. Sturmer T, Buring JE, Lee IM, Gaziano JM, Glynn RJ (2006) Metabolic abnormalities and risk for colorectal cancer in the physicians’ health study. Cancer Epidemiol Biomark Prev 15:2391–2397

    Article  Google Scholar 

  24. Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F (2001) Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomark Prev 10:937–941

    CAS  Google Scholar 

  25. Bird CL, Ingles SA, Frankl HD, Lee ER, Longnecker MP, Haile RW (1996) Serum lipids and adenomas of the left colon and rectum. Cancer Epidemiol Biomark Prev 5:607–612

    CAS  Google Scholar 

  26. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC (1995) Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 122:327–334

    CAS  PubMed  Google Scholar 

  27. Giovannucci E, Colditz GA, Stampfer MJ, Willett WC (1996) Physical activity, obesity, and risk of colorectal adenoma in women (United States). Cancer Causes Control 7:253–263

    Article  CAS  PubMed  Google Scholar 

  28. Kono S, Imanishi K, Shinchi K, Yanai F (1993) Serum lipids and left-sided adenomas of the large bowel: an extended study of self-defense officials in Japan. Cancer Causes Control 4:117–121

    Article  CAS  PubMed  Google Scholar 

  29. Platz EA, Giovannucci E, Rimm EB, Rockett HR, Stampfer MJ, Colditz GA et al (1997) Dietary fiber and distal colorectal adenoma in men. Cancer Epidemiol Biomark Prev 6:661–670

    CAS  Google Scholar 

  30. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE et al (2006) C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomark Prev 15:750–755

    Article  CAS  Google Scholar 

  31. Kim JH, Lim YJ, Kim YH, Sung IK, Shim SG, Oh SO et al (2007) Is metabolic syndrome a risk factor for colorectal adenoma? Cancer Epidemiol Biomark Prev 16:1543–1546

    Article  CAS  Google Scholar 

  32. Morita T, Tabata S, Mineshita M, Mizoue T, Moore MA, Kono S (2005) The metabolic syndrome is associated with increased risk of colorectal adenoma development: the Self-Defense Forces health study. Asian Pac J Cancer Prev 6:485–489

    PubMed  Google Scholar 

  33. Wang YY, Lin SY, Lai WA, Liu PH, Sheu WH (2005) Association between adenomas of rectosigmoid colon and metabolic syndrome features in a Chinese population. J Gastroenterol Hepatol 20:1410–1415

    Article  PubMed  Google Scholar 

  34. Tsilidis KK, Erlinger TP, Rifai N, Hoffman S, Hoffman-Bolton J, Helzlsouer KJ et al (2008) C-reactive protein and colorectal adenoma in the CLUE II cohort. Cancer Causes Control 19:559–567

    Article  PubMed  Google Scholar 

  35. Masharani U, Karam JH, German MS (2004) Pancreatic hormones and diabetes mellitus. In: Greenspan FS, Gardner DG (eds) Basic and clinical endocrinology. McGraw-Hill, New York, pp 658–746

  36. Powell DR, Suwanichkul A, Cubbage ML, DePaolis LA, Snuggs MB, Lee PD (1991) Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J Biol Chem 266:18868–18876

    CAS  PubMed  Google Scholar 

  37. Rochman H (1980) Hemoglobin A1c and diabetes mellitus. Ann Clin Lab Sci 10:111–115

    CAS  PubMed  Google Scholar 

  38. Kwiterovich PO Jr, White S, Forte T, Bachorik PS, Smith H, Sniderman A (1987) Hyperapobetalipoproteinemia in a kindred with familial combined hyperlipidemia and familial hypercholesterolemia. Arteriosclerosis 7:211–225

    PubMed  Google Scholar 

  39. Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062

    Article  PubMed  Google Scholar 

  40. Giovannucci E (2001) Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131:3109S–3120S

    CAS  PubMed  Google Scholar 

  41. Palmqvist R, Stattin P, Rinaldi S, Biessy C, Stenling R, Riboli E et al (2003) Plasma insulin, IGF-binding proteins-1 and -2 and risk of colorectal cancer: a prospective study in northern Sweden. Int J Cancer 107:89–93

    Article  CAS  PubMed  Google Scholar 

  42. Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687

    Article  PubMed  Google Scholar 

  43. Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE (2007) Circulating insulin and C-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomark Prev 16:161–164

    Article  CAS  Google Scholar 

  44. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E (2001) Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47:444–450

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We appreciate the continued efforts of the staff members at the Johns Hopkins George W. Comstock Center for Public Health Research and Prevention in the conduct of the CLUE II study. We also thank Gary Bradwin, director of Dr. Rifai’s laboratory, and Yuzhen Tao, in the laboratory of Dr. Pollak, for overseeing the laboratory assays. This research was supported by a grant from the American Institute for Cancer Research, and Public Health Service research grants CA86308 (Early Detection Research Network) from the National Cancer Institute, and AG18033 from the National Institute of Aging, National Institutes of Health, Department of Health and Human Services. Konstantinos Tsilidis was funded by a J. William Fulbright grant and a scholarship from the Hellenic State Scholarships Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Elizabeth A. Platz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsilidis, K.K., Brancati, F.L., Pollak, M.N. et al. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes Control 21, 1–10 (2010). https://doi.org/10.1007/s10552-009-9428-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-009-9428-6

Keywords

Navigation